Sign inJoin waitlistJoin the waitlist

Alexandra Stevens

Associate Director, Basic and Translational Research, Leukemia Program · Baylor College of Medicine

Credentials: · · · ·

History

Baylor College of Medicine
Present
Baylor College of Medicine
Present

Icahn School of Medicine at Mount Sinai
2014–2015
Pediatric Hematology/Oncology
Baylor College of Medicine
2011–2014
Pediatrics
2008–2011
Columbia University–College of Physicians and Surgeons.In
Baylor College of Medicine
2003–2007
Duke University

Research

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance
Blood Advances · 2017 · First of 5 authors · 70 citations
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Review · Current Oncology Reports · 2021 · 56 citations
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation
Blood Advances · 2019 · First of 22 authors · 49 citations

Michele Redell
16 papers
Andrea Marcogliese
6 papers
Joanna Yi
5 papers
MT
Maci Terrell
5 papers
Anil George
4 papers · 4 as a resident
Eric Schafer
4 papers
Judith Campbell
4 papers
Zachary Prudowsky
4 papers · 1 as a fellow
Amber Gibson
3 papers · 1 as a fellow
Branko Cuglievan
3 papers
David Steffin
3 papers
Ghayas Issa
3 papers

Grants

Exploiting the Metabolic Dependencies of Pediatric AML
National Cancer Institute · K08
Contact PI · $1M · Baylor College of Medicine
2023–2028

Clinical trials

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Principal investigator · Recruiting · Phase 1
Children's Oncology Group
2025–2028
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
Principal investigator · Completed · Early phase 1
Baylor College of Medicine
2018–2025
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Site PI · Recruiting · Phase 3
Children's Oncology Group
2020–2029